PD-L1 Protein (His tag)

N° du produit ABIN7668351

Protéine Recombinant PD-L1 exprimée dans Escherichia coli (E. coli).

Aperçu rapide pour PD-L1 Protein (His tag) (ABIN7668351)

Antigène: PD-L1 (CD274 (PD-L1))

Type de proteíne: Recombinant

Activité biologique: Inactive

Origine: Humain

Source: Escherichia coli (E. coli)

Pureté: > 95 %

Détail du produit

Purification/Conjugué: Cette PD-L1 protéine est marqué à la His tag.

Fonction: Recombinant Human PD-L1/B7-H1/CD274 protein (His tag)

Séquence: Phe19-Thr 239

Purification: > 95 % as determined by reducing SDS-PAGE.

Stérilité: 0.2 μm filtered

niveau d'endotoxine: < 10 EU/mg of the protein as determined by the LAL method.

Information d'application

Restrictions: For Research Use only

Stockage

Format: Lyophilized

Reconstitution: It is recommended that sterile water be added to the vial to prepare a stock solution of 0.5 mg/mL. Concentration is measured by UV-Vis.

Buffer: Lyophilized from sterile PBS, pH 7.4.
Normally 5 % -8 % trehalose, mannitol and 0.01 % Tween 80 are added as protectants before lyophilization.

Stock: 4 °C,-20 °C,-80 °C

Stockage commentaire: Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.

Date de péremption: 12 months

Détail du antigène

Antigène: PD-L1 (CD274 (PD-L1))

Autre désignation: PD-L1,B7-H1,CD274

Sujet: CD274, also known as B7-H1 or programmed death ligand 1 (PD-L1), is a 40 kD type I transmembrane protein and a member of the B7 family within the immunoglobulin receptor superfamily. Programmed death-1 ligand-1 (PD-L1, CD274, B7-H1) has been identified as the ligand for the immunoinhibitory receptor programmed death-1(PD1/PDCD1) and has been demonstrated to play a role in the regulation of immune responses and peripheral tolerance. By binding to PD1 on activated T-cells and B-cells, PD-L1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression. Accordingly, it leads to growth of immunogenic tumor growth by increasing apoptosis of antigen specific T cells and may contribute to immune evasion by cancers. PD-L1 thus is regarded as promising therapeutic target for human autoimmune disease and malignant cancers.,B7 homolog 1,B7-H1,B7H1,CD274,PD-L1,PDCD1 ligand 1,PDCD1L1,PDCD1LG1,PDL1,Programmed Cell Death 1 Ligand 1,Programmed death ligand 1

Poids moléculaire:

calculated_mw: 24.1 kDa

observed_mw: 31 kDa

UniProt: Q9NZQ7

Pathways: Cancer Immune Checkpoints